MARKET

CTLT

CTLT

Catalent Inc
NYSE
56.30
-0.62
-1.09%
After Hours: 56.30 0 0.00% 19:32 04/12 EDT
OPEN
56.78
PREV CLOSE
56.92
HIGH
57.04
LOW
56.20
VOLUME
1.96M
TURNOVER
0
52 WEEK HIGH
67.54
52 WEEK LOW
31.45
MARKET CAP
10.18B
P/E (TTM)
-7.8443
1D
5D
1M
3M
1Y
5Y
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S. The company is developing the next generation of weight loss and diabetes drugs. Novo has been established as a leader in the obesity market. Eli Lilly and Co. And Novo will remain the two entrenched players in this duopoly.
Benzinga · 1d ago
BUZZ-BMO starts Novo Nordisk US shares with "overweight', Street-high PT
BMO Capital Markets starts Novo Nordisk's U.S.-listed shares with "outperform" and a Street-high PT of $163. The Danish drugmaker's stock gains 1% to $126.66. EU drug regulator found evidence that a class of diabetes drugs are linked to suicidal thoughts. BMO raises Eli Lilly's US shares to $900.
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanks · 1d ago
Guru Fundamental Report for CTLT - Benjamin Graham
NASDAQ · 2d ago
Top 10 best performing S&P 500 health care stocks of 2024
19 of the 65 health care stocks within the S&P 500 have topped the broader market's performance in 2024. The health care sector traditionally has been seen as a defensive sector. The top 10 best performing health care companies in 2024 are all in the Health Care sector.
Seeking Alpha · 3d ago
Health Care Sector Update for 04/08/2024: ALNY, LEGN, JNJ, NVO, CTLT, XLV, IBB
NASDAQ · 5d ago
UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
Novo Nordisk refiles application to U.S. FTC for approval of $16.5 billion deal to buy manufacturing subcontractor Catalent. Novo Nordisk Foundation said last month it agreed to buy Catalent to boost output of Wegovy drug. Catalent would sell three of its fill-finish sites to Novo for $11 billion.
Reuters · 5d ago
NOVO NORDISK FOUNDATION: WE HAVE REFILED APPLICATION TO U.S. FEDERAL TRADE COMMISSION FOR APPROVAL OF CATALENT ACQUISITION AFTER INFORMAL DISCUSSION
Reuters · 5d ago
More
About CTLT
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Webull offers Catalent Inc stock information, including NYSE: CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.